Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France

Epidemiology and Infection

Volumn 132, Issue 4, 2004, Pages 699-708

  Lucidarme, D ^a   Bruandet, A ^b   Ilef, D ^c   Harbonnier, J ^d   Jacob, C ^e   Decoster, A ^a   Delamare, C ^f   Cyran, C ^g   Van Hoenacker, A F ^g   Fremaux D ^g   Josse, P ^h   Emmanuelli, J ^b   Le Strat, Y ^b   Desenclos, J C ^b   Filoche, B ^a  

^a Centre Hospitalier Saint Philibert GHICL   (France)

^b INSTITUT DE VEILLE SANITAIRE   (France)

^c Epidemiologie de Nord Picardie   (France)

^d Centre Boris Vian   (France)

^e Centre Baudelaire   (France)

^f CENTRE HOSPITALIER   (France)

^g UFATT ^*  (France)

^h Ufatt   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; COTTON; DATA ANALYSIS; DRUG ABUSE; FEMALE; FOLLOW UP; FRANCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INJECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PROSPECTIVE STUDY; RISK FACTOR; SEROCONVERSION; SYRINGE; CLINICAL TRIAL; MULTICENTER STUDY; QUESTIONNAIRE; SUBSTANCE ABUSE; VIROLOGY;

ADULT; COHORT STUDIES; FEMALE; FRANCE; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SYRINGES;

EID: 4143126855     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S095026880400247X     Document Type: Article

References (31)

1. Dubois F, Desenclos JC, Mariotte N, et al. Hepatitis C in a French population-based survey, 1994; seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group. Hepatology 1997; 25: 1490-1496.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
3. Conry Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691-1696.
4. Hernandez Aguado I, Ramos Rincon JM, Avinio MJ, et al. Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. Eur J Epidemiol 2001; 17: 539-544.
5. Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995. Med J Aust 1997; 167: 17-20.
6. Six C, Hamers F, Brunet JB. Infections à VIH, VHC et VHB chez les résidents des centres de soins spécialisés pour toxicomanes avec hébergement 1993-1998 [HIV, HCV and HBV infections in drug-user attendees of case centres with housing 1993-1998]. BEH 1999; 32: 1-4.
7. Valenciano M, Emmanuelli J, Lert F. Unsafe injecting practices among attendees of syringe exchange programmes in France. Addiction 2001; 96: 597-606.
8. Bello PY, Pasquier C, Gourney P, et al. Assessment of a hepatitis C virus antibody assay in saliva for epidemiological studies. Eur J Clin Microbiol Infect Dis 1998; 17: 570-572.
9. McIntyre MG, Laszlo J, Appleyard K, et al. Modified enzyme immunoassay to detect hepatitis C virus antibodies in oral fluid. Eur J Clin Microbiol Infect Dis 1996; 15: 882-884.
10. Lucidarme D, Decoster A, Delamare C, et al. Etude inter-laboratoires de la détection des anticorps anti-VHC sur prélèvements salivaires [An inter-laboratory study of anti-HCV antibody detection in saliva samples]. Gastroenterol Clin Biol 2003; 27: 159-162.
11. Bouyer J, Hemon D, Cordier S, et al. Epidemiologie, principes et méthodes quantitatives [Epidemiology, principles and quantitative methods]. INSERM éditions 1995; 184.
12. Cox DR. Regression models and lifetables (with discussion). J Roy Stat Soc (B) 1972; 34: 187-220.
13. Des Jarlais DC, Paone D, Milliken J, et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet 1999; 353: 1657-1661.
14. Crofts N, Aitken CK, Kaldor JM. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Austr 1999; 170: 220-221.
15. Lucidarme D, Foutrein P, Creusy C, et al. Prévalence des marqueurs des hépatites C, B, et D, et aspects histopathologiques dans un groupe de toxicomanes intraveineux [Prevalence of serological markers of hepatitis C, B and D and histological aspects in intravenous drug users]. Gastroenterol Clin Biol 1994; 18: 964-968.
16. Schmitt C, Bertel J, Jacob C. Incidence of serological markers of hepatitis B and C viruses and HIV in a population of drug abusers hospitalized from 1990 to 1992. Ann Med Int 1994; 145: 7-12.
17. Garfein RS, Doherty MC, Monterroso ER, et al. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (Suppl 1): S11-S19.
18. Patrick DM, Tyndall MW, Cornelisse PGA, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Can Med Assoc J 2001; 165: 889-895.
19. Van Ameijden EJ, Van den Hoek JA, Mientjes GH, et al. A longitudinal study on the incidence and transmission patterns of HIV, HBV, HCV infection among drug users in Amsterdam. Eur J Epidemiol 1993; 9: 255-262.
20. Hagan H, Thiede H, Weiss NS, et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91: 42-46.
21. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155: 645-653.
22. Villano SA, Vlahov D, Nelson KE, et al. Incidence and risk factors for hepatitis C among drug users in Baltimore, Maryland. J Clin Microbiol 1997; 35: 3274-3277.
23. Broers B, Junet C, Bourquin M, et al. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS 1998; 12: 2059-2066.
24. Hahn JA, Page Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002; 186: 1558-1564.
25. Brunton C, Kemp R, Raynel P, et al. Cumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users. NZ Med J 2000; 113: 98-101.
26. Miller CL, Johnston C, Spitall PM, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002; 36: 737-742.
27. Rezza G, Sagliocca L, Zaccarelli M, et al. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence. Scand J Infect Dis 1996; 28: 27-29.
28. Van Beek I, Dwyer R, Dore GJ, et al. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. Br Med J 1998; 317: 433-437.
29. Bourgeois P, Lettière M, Quesada J. Social misery and the sanctions of substance abuse: confronting HIV risk among homeless heroin addicts in San Francisco. Social Problems 1997; 44: 155-173.
30. Hope VD, Judd A, Hickman M, et al. Prevalence of Hepatitis C among injection drug users in England and Wales: is harm reduction working? Am J Public Health 2001; 91: 38-42.
31. Emmanuelli J. Tendances en matière de réduction des risques chez les usagers de drogues par voie IV an 30/12/2001, phénomènes émergents liés aux drogues en 2001 [Trends concerning risk-reduction programmes in injecting drug users up to 30/12/2001, emerging phenomenons linked to drugs in 2001]. Rapport TREND 2002; 1 OFDT.